Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
- 1 May 1987
- journal article
- research article
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 78 (3), 273-280
- https://doi.org/10.1016/0022-510x(87)90041-4
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Long‐term follow‐up of early dopa treatment in Parkinson's diseaseAnnals of Neurology, 1986
- The dopamine neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces histological lesions in the hypothalamus of the common marmosetNeuroscience Letters, 1986
- The Role of l-DOPA Holiday in the Long-Term Management of Parkinsonʼs DiseaseClinical Neuropharmacology, 1986
- Neural mechanisms mediating 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the monkey: Relative contributions of the striatopallidal and striatonigral pathways as suggested by 2-deoxyglucose uptakeNeuroscience Letters, 1986
- Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus coeruleusNeuroscience Letters, 1985
- Permanent human parkinsonism due to 1‐methy 1–4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)Neurology, 1985
- AETIOLOGY OF PARKINSON'S DISEASEThe Lancet, 1983
- Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog SynthesisScience, 1983
- Analysis of the clinical problems in parkinsonism and the complications of long‐term levodopa therapyNeurology, 1979
- ParkinsonismNeurology, 1967